Jean-Marc Classe is an expert in Oncology at Institut de Cancérologie de l'Ouest (France). As of October 2026, ScienceLeadR ranks Jean-Marc Classe in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Jean-Marc Classe has authored 257 publications, the most recent in 2026, and is an investigator in 9 clinical trials. SLR score: 791 (community average: 125). How the SLR is computed.

LeadR Profile

791 ScienceLeadR Reputation 791
Network Map

Oncology

Subspecialties: Gynecology - Surgery - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1993 - 2026

Source: PubMed

Institut de Cancérologie de l'Ouest

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 257

Citations

Citations: 6 231 1st author: 42 Last author: 38 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database.
PMID 42013623 — cytoreduction surgical procedures, lymph nodes, ovary, neoplasms, drug therapy, lymph, ovarian neoplasms, therapeutics, dissection, prognosis, chemotherapy
Eur J Surg Oncol20260
[Corrigendum to: "French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer" [Bull Cancer 2026;113:191-207]].
PMID 41966948 — ovary, neoplasms, carcinoma, ovarian epithelial
Bull Cancer20260
[French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer].
PMID 41620325 — ovary, neoplasms, rehabilitation, therapeutics, carcinoma, ovarian epithelial
Bull Cancer20260
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas.
PMID 39481880 — poly(adp-ribose) polymerases, progression-free survival, ovary, genital neoplasms, female, neoplasms, poly adenosine diphosphate ribose, drug therapy, respect, ovarian neoplasms, therapeutics, prognosis, chemotherapy
Int J Gynecol Cancer20254
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
PMID 40329152 — breast neoplasms, nomograms, neoplasms, breast
Breast Cancer Res Treat20250

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Study Director: 1

By phase:

N/A 7
Phase 3 2

By status:

Completed 5
Active not recruiting 1
Recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 8
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 8

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map